4.7 Article

Evolution of Sequence Type 4821 Clonal Complex Hyperinvasive and Quinolone-Resistant Meningococci

Journal

EMERGING INFECTIOUS DISEASES
Volume 27, Issue 4, Pages 1110-1122

Publisher

CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2704.203612

Keywords

-

Funding

  1. Wellcome Trust
  2. European Union
  3. National Natural Science Foundation of China [81872909, 81601801]
  4. Shanghai Rising-Star Program from Shanghai Municipal Science and Technology Commission [17QA1403100]
  5. Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai [2017YQ039]
  6. 13th Five-Year Project of National Health and Family Planning Commission of the People's Republic of China [2017ZX10303405004, 2017ZX10103009-003]

Ask authors/readers for more resources

The study revealed the expansion of quinolone-resistant Neisseria meningitidis clone China(CC4821-R1-C/B) from China to other countries, highlighting the potential of causing a pandemic on a global scale.
Expansion of quinolone-resistant Neisseria meningitidis clone China(CC4821-R1-C/B) from sequence type (ST) 4821 clonal complex (CC4821) caused a serogroup shift from serogroup A to serogroup C invasive meningococcal disease (IMD) in China. To determine the relationship among globally distributed CC4821 meningococci, we analyzed whole-genome sequence data from 173 CC4821 meningococci isolated from 4 continents during 1972-2019. These meningococci clustered into 4 sublineages (1-4); sublineage 1 primarily comprised of IMD isolates (41/50, 82%). Most isolates from outside China (40/49, 81.6%) formed a distinct sublineage, the Europe-USA cluster, with the typical strain designation B:P1.17-6,23:F3-36:ST-3200(CC4821), harboring mutations in penicillin-binding protein 2. These data show that the quinolone-resistant clone China(CC4821-R1-C/B) has expanded to other countries. The increasing distribution worldwide of serogroup B CC4821 raises the concern that CC4821 has the potential to cause a pandemic that would be challenging to control, despite indirect evidence that the Trumenba vaccine might afford some protection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available